Entolimod candidate granted U.S. patent extension
The entolimod compound is currently being developed by the company to serve as a treatment for acute radiation syndrome (ARS) caused by high levels of radiation exposure. The candidate consists of a recombinant protein that aids in the immune response against exposure. Clinical studies have shown that the drug is safe to use. The company reports mild flu-like symptoms, elevation of liver enzymes and decreased blood pressure in human studies. At this time, there are no approved treatments for ARS.
The protein stimulates immune response through the interaction with toll-like receptor 5 (TLR5), which plays a key role in the immune response process.
The company stated that the candidate shows cytotoxic effects to tumor cells, and a Phase One clinical study is currently taking place in the Russian Federation in advanced cancer patients.
The company holds 14 patents in the U.S. for developmental candidates and technology associated with oncology and biological defense applications.
“With the market's increasing focus on immunotherapies for multiple indications, including oncology, CBLI has a strong and varied patent estate that underpins the company's value," CBL CEO Yakov Kogan said.